A Multi-Center, Double-Masked, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil
| Registry | NCT03751098, acronym MIST-2 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional; randomized, crossover, masking: double, diagnostic |
| Enrollment | 76 (Actual) |
| Sponsor | Eyenovia Inc. (Industry) |
| Conditions | Mydriasis |
| Interventions | Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo (Drug) |
| Dates | start 2018-12-01, primary completion 2019-01-21, completion 2019-01-21, first posted 2018-11-23, last updated 2022-03-18 |
| Locations | 2 sites in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Mydriasis All trials of Tropicamide/Phenylephrine ophthalmic solution (TR/PE) All trials of Placebo
This study evaluated pupil dilation after administration of fixed combination tropicamide-phenylephrine (TR/PH) vs. placebo. Participants attended 3 visits. At each visit, after baseline measurements, either the study drug or placebo was administered to both eyes, then pupil dilation and safety assessments were performed at specific time intervals.
Volunteer participants were screened for study eligibility during a Screening Visit and enrolled after signing the study-specific informed consent form. Subjects meeting all inclusion/exclusion criteria were scheduled for 3 treatment visits, which were at least 2 days, but no more than 7 days apart. At each treatment visit, baseline measurements were taken, then either the study drug or placebo was administered to both eyes. Afterwards, efficacy and safety assessments were performed at 20, 35, 50, 65, 80, 120, and 180 minutes. Participants' treatment assignments for each treatment visit were equally randomized using 1 of 2 sequences - ABB or BAA, where A was the study drug and B was the placebo.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| 1-TR/PE, 2-Placebo, 3-Placebo | Other | Drug: Tropicamide/Phenylephrine ophthalmic solution (TR/PE); Drug: Placebo | Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye. |
| 1-Placebo, 2-Placebo, 3-TR/PE | Other | Drug: Tropicamide/Phenylephrine ophthalmic solution (TR/PE); Drug: Placebo | Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye. |
Sex: All, accepts healthy volunteers
Inclusion Criteria: * Ability to provide written consent and return for all study visits * Photopic pupil diameter <= 3.5 mm in each eye Exclusion Criteria: * Allergy to phenylephrine hydrochloride, tropicamide, or benzalkonium chloride * History of benign prostatic hyperplasia * Use of a benzodiazepine, monoamine oxidase inhibitor, tricyclic antidepressant, anticonvulsant, or cholinergic drug * History of closed-angle glaucoma * Anatomically narrow anterior chamber angles * Ocular surgery or laser treatment of any kind * History of chronic or acute uveitis * History of traumatic iritis or hyphema * History of traumatic mydriasis or angle recession * History of heterochromia * Irregularly-shaped pupil secondary to ocular trauma or congenital defect. * History of neurogenic pupil disorder * History of anterior chamber intraocular lens (IOL) or iris-fixated IOL * History of iris surgery, iris atrophy, or iris-cornea apposition/touch * Unwilling or unable to discontinue use of contact lenses at treatment visits. * Current active eye disease for which topical or systemic ophthalmic medication is necessary, except for dry eye disease managed using artificial tears. * Presence of a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment and/or follow-up * Pregnancy or lactation
| Milestone | 1-TR/PE, 2-Placebo, 3-Placebo | 1-Placebo, 2-Placebo, 3-TR/PE |
|---|---|---|
| Started | 37 | 33 |
| Completed | 37 | 32 |
| Not completed | 0 | 1 |
Time frame: Adverse event data was collected over each participant's study participation period, which was a maximum of 14 days.
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|---|---|---|
| Tropicamide/Phenylephrine | 0/69 (0.0%) | 0/69 (0.0%) | 2/69 (2.9%) |
| Placebo | 0/70 (0.0%) | 0/70 (0.0%) | 0/70 (0.0%) |
| Term | Organ system | Tropicamide/Phenylephrine | Placebo |
|---|---|---|---|
| Photophobia | Eye disorders | 1/69 | 0/70 |
| Instillation site pain | General disorders | 1/69 | 0/70 |
| Facility | City | Country | Status |
|---|---|---|---|
| Keystone Research | Austin, Texas | United States | |
| R&R Research | San Antonio, Texas | United States |